Auxilium's Xiaflex will get US arthritis panel review
This article was originally published in Scrip
Executive Summary
Auxilium Pharmaceuticals says the US FDA's arthritis advisory panel is tentatively scheduled to review its investigational treatment Xiaflex (collagenese clostridium histolyticum) for Dupuytren's contracture on September 16th.